[go: up one dir, main page]

US4067969A - Anthracycline glycosides, their preparation and use - Google Patents

Anthracycline glycosides, their preparation and use Download PDF

Info

Publication number
US4067969A
US4067969A US05/722,689 US72268976A US4067969A US 4067969 A US4067969 A US 4067969A US 72268976 A US72268976 A US 72268976A US 4067969 A US4067969 A US 4067969A
Authority
US
United States
Prior art keywords
deoxy
compound according
demethoxy
compound
adriamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/722,689
Inventor
Sergio Penco
Federico Arcamone
Aurelio Di Marco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmaceutici Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmaceutici Italia SpA filed Critical Farmaceutici Italia SpA
Application granted granted Critical
Publication of US4067969A publication Critical patent/US4067969A/en
Assigned to FARMITALIA CARLO ERBA S.P.A., reassignment FARMITALIA CARLO ERBA S.P.A., MERGER (SEE DOCUMENT FOR DETAILS). 12-2-78 Assignors: CARLO ERBA S.P.A., SOCIETA' FARMACEUTICI ITALIA S.P.A., KNOWN AS FARMITALIA S.P.A.
Assigned to FARMITALIA CARLO ERBA S.R.L. reassignment FARMITALIA CARLO ERBA S.R.L. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: FARMITALIA CARLO ERBA S.P.A.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to novel antitumor glycosides of the anthracycline series, which are derivatives of the known antitumor glycosides daunomycin and adriamycin, as well as their preparation and their use in treating mammalian tumors.
  • the invention also relates to certain novel intermediates used in preparing the glycosides of the invention.
  • Daunomycin and adriamycin are known antitumor antibiotics which are described and claimed in British Pat. Nos. 1,033,383 and 1,161,278 and 1,217,133, respectively, all of which are owned by the unrecorded assignee hereof.
  • anthracycline glycoside antibiotics which are 4'-deoxy-daunomycins and 4'-deoxy-adriamycins.
  • the invention provides a new process for preparing these antibiotics.
  • the invention provides certain novel intermediates used in the new process.
  • the invention provides a method of using the novel antibiotics in the treatment of various forms of mammalian tumors.
  • the new anthracycline glycoside antibiotics of the invention are compounds of the formula of (IV) and (XII) ##STR1## wherein, when R 1 and R 3 are hydrogen, R 2 is hydrogen, methyl, methoxy, chlorine or bromine; when R 1 and R 2 are hydrogen, R 3 is a C 1 -C 4 alkoxy group; and when R 2 is hydrogen, R 1 and R 3 are both methyl, methoxy, chlorine or bromine.
  • the new anthracycline glycoside antibiotics (IV) of the invention are condensation products of (a) a tetracyclic aglycone having a hydroxy-anthraquinone chromophoric system of the formula: ##STR2## wherein R 1 , R 2 and R 3 are as defined above and (b) the novel halo sugar: 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexopyranosyl chloride: ##STR3##
  • the process for preparing the novel compounds of formula (IV) involves a condensation reaction between aglycone (I) and halo sugar (II), which is carried out in an inert organic solvent such as chloroform, methylene dichloride, diethyl ether, tetrahydrofuran, acetonitrile, or dimethylformamide in the presence of a soluble silver salt, such as silver trifluoromethan sulphonate, as a catalyst.
  • a dehydrating agent such as a molecular sieve is preferably also present in the reaction mixture.
  • the new anthracycline glycoside antibiotics (XII) of the invention are prepared by reacting a compound of the formula (IV) with bromine to obtain the 14-bromo-derivative thereof which is then hydrolyzed with sodium formate to form a compound of formula (XII) which may then be isolated as the hydrochloride.
  • novel intermediates which comprise a further aspect of the invention are the following compounds of the formulae (VI), (VII), (VIII), (IX), (IXa) and (II), the latter compound being the halo sugar which is the starting material for the preparation of (IV). ##STR4##
  • halo sugar (II) is prepared, starting from methyl-N-trifluoroacetyl-daunosaminide (VI).
  • Compound (VI) is reacted in dry pyridine with methane sulphonyl chloride and thereby converted in a quantitative yield to its 4-O-mesyl-derivative (VII), which by treatment with sodium iodide in methylethylketone leads to the 4-iodo-derivative (VIII).
  • novel compounds of the formula (IV) and (XII) exhibit antimitotic activity, and thus are useful in treating certain mammalian tumors.
  • the daunomycin derivatives prepared in accordance with Example 4 can then be treated as in Example 3 to obtain the corresponding adriamycin derivatives.
  • the antitumor activity of a representative number of the novel antibiotic compounds of the invention was evaluated on several transplanted tumors in mice in comparison with the known antitumor agents daunomycin and adriamycin.
  • mice were intraperitoneally inoculated with 10 5 leukemia cells/mouse and then treated intraperitoneally one day after the tumor inoculation with varying doses of the compounds under examination.
  • the average survival time percentage and the number of long term survivors are given in Table 1.
  • Inbred C 3 H female mice were intravenously inoculated with a suspension of Leukemia lymphonodes and spleen cells (2 ⁇ 10 6 Leukemia cells/mouse) and treated intravenously on days 1,2 and 3 after inoculation with the compounds under examination.
  • the average survival time percentage is given in Table 2.
  • mice Male CDF 1 mice were intraperitoneally inoculated with 10 6 leukemia cells/mouse and treated intraperitoneally on the first day after inoculation with different doses of the compounds under examination.
  • the average survival time percentage is given in Table 3.
  • mice were subcutaneously grafted with fragments of neoplastic (Solid Sarcoma 180) tissue and treated intravenously on days 1, 2, 3, 4 and 5 after inoculation with different doses of the compounds under examination.
  • the growth of the tumors was evaluated by caliper measurement on the 11th day after the tumor implants. The results are given in Table 4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

The novel compounds, 4'-deoxy-daunomycin and 4'-deoxy-adriamycin, as well as derivatives thereof are useful as anti-tumor antibiotics. These compounds are prepared by condensing the corresponding aglycone with a novel trifluoracetyl protected reactive halo sugar which is 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexopyranosyl chloride.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel antitumor glycosides of the anthracycline series, which are derivatives of the known antitumor glycosides daunomycin and adriamycin, as well as their preparation and their use in treating mammalian tumors. The invention also relates to certain novel intermediates used in preparing the glycosides of the invention.
2. The Prior Art
Daunomycin and adriamycin are known antitumor antibiotics which are described and claimed in British Pat. Nos. 1,033,383 and 1,161,278 and 1,217,133, respectively, all of which are owned by the unrecorded assignee hereof.
SUMMARY OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a new class of anthracycline glycoside antibiotics which are 4'-deoxy-daunomycins and 4'-deoxy-adriamycins.
In another aspect, the invention provides a new process for preparing these antibiotics.
In a further aspect, the invention provides certain novel intermediates used in the new process.
In yet another aspect, the invention provides a method of using the novel antibiotics in the treatment of various forms of mammalian tumors.
The new anthracycline glycoside antibiotics of the invention are compounds of the formula of (IV) and (XII) ##STR1## wherein, when R1 and R3 are hydrogen, R2 is hydrogen, methyl, methoxy, chlorine or bromine; when R1 and R2 are hydrogen, R3 is a C1 -C4 alkoxy group; and when R2 is hydrogen, R1 and R3 are both methyl, methoxy, chlorine or bromine.
The new anthracycline glycoside antibiotics (IV) of the invention are condensation products of (a) a tetracyclic aglycone having a hydroxy-anthraquinone chromophoric system of the formula: ##STR2## wherein R1, R2 and R3 are as defined above and (b) the novel halo sugar: 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexopyranosyl chloride: ##STR3##
After the condensation reaction, the protecting trifluoroacetyl group (--COCF3) is removed under alkaline conditions to obtain (IV) as the final product.
The process for preparing the novel compounds of formula (IV) involves a condensation reaction between aglycone (I) and halo sugar (II), which is carried out in an inert organic solvent such as chloroform, methylene dichloride, diethyl ether, tetrahydrofuran, acetonitrile, or dimethylformamide in the presence of a soluble silver salt, such as silver trifluoromethan sulphonate, as a catalyst. A dehydrating agent such as a molecular sieve is preferably also present in the reaction mixture.
The new anthracycline glycoside antibiotics (XII) of the invention are prepared by reacting a compound of the formula (IV) with bromine to obtain the 14-bromo-derivative thereof which is then hydrolyzed with sodium formate to form a compound of formula (XII) which may then be isolated as the hydrochloride.
The novel intermediates which comprise a further aspect of the invention are the following compounds of the formulae (VI), (VII), (VIII), (IX), (IXa) and (II), the latter compound being the halo sugar which is the starting material for the preparation of (IV). ##STR4##
All of these intermediates are amino sugars of which the progenitor, i.e., the basic, unsubstituted amino sugar is 3-amino-2,3,4,6-tetradeoxy-L-threo-hexose: ##STR5## This amino sugar (V) was also previously unknown and may be obtained as its N-trifluoroacetyl derivative (IX) from methyl-N-trifluoroacetyl-daunosaminide (VI).
According to the invention, halo sugar (II) is prepared, starting from methyl-N-trifluoroacetyl-daunosaminide (VI). Compound (VI) is reacted in dry pyridine with methane sulphonyl chloride and thereby converted in a quantitative yield to its 4-O-mesyl-derivative (VII), which by treatment with sodium iodide in methylethylketone leads to the 4-iodo-derivative (VIII).
Catalytic hydrogenation of compound (VIII) followed by acid hydrolysis of the resulting methyl glycoside, yields 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexopyranose (IX). Treatment of this intermediate (IX) with p-nitrobenzyl chloride in dry pyridine gives the corresponding 1-p-nitrobenzoate (IXa), which upon treatment at 0° C with dry hydrogen chloride in anhydrous methylene dichloride yields the desired 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexopyranosyl chloride (II).
When in the aglycone of formula (I), R1 = R2 = H and R3 is methoxy, 4'-deoxy-daunomycin is finally obtained and isolated as its hydrochloride. Subsequent treatment in accordance with the procedures described in U.S. Pat. No. 3,803,124 yields 4'-deoxyadriamycin which is also isolated as its hydrochloride.
The novel compounds of the formula (IV) and (XII) exhibit antimitotic activity, and thus are useful in treating certain mammalian tumors.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following examples are given to illustrate the invention without, however, being a limitation thereof. All parts given are by weight, unless otherwise indicated.
EXAMPLE 1 Preparation of the intermediate 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexopyranosyl chloride (II)
5.2 g of methyl N-trifluoroacetyl daunosaminide (VI), dissolved in 40 ml of anhydrous pyridine, were treated at -5° C with 8 ml of methane sulphonyl chloride. The reaction mixture was kept overnight at 4° C and then evaporated to a residue under vacuum. The resulting residue was dissolved in 300 ml of chloroform and washed with water until the water was neutral. The organic phase was dried over anhydrous sodium sulphate and then evaporated to yield 4.2 g of the crystalline 4-O-mesyl-derivative (VII) m.p. 169°-170° C; [α]D -160° (c = 0.1 in CHCl3); m/e 304 (M--OCH3); PMR (CDCl3 --DMSO-d6 4:1) : 1.26δ (d, J = 6.5 Hz, CH3 --C-5), 3.18δ (s, CH3 OSO2), 3.38δ (s, CH3 O), 4.80δ (broad s, WH = 5.5 Hz, C--1H).
8.7 g of the dried compound (VII) were dissolved in 150 ml of methylethylketone, treated with 5 g of sodium iodide and heated at reflux temperature for 24 hours. The reaction mixture was evaporated to a residue which was then suspended in 200 ml of chloroform. The insoluble material was filtered off, and the organic phase was washed with a 3% aqueous sodium thiosulphate solution and then with water. The washed organic phase was evaporated to a residue under vacuum to yield a crude product. The crude product was purified by chromatography on a column of silicic acid using benzene : acetone (20:1) as the eluent. There were obtained 2.3 g of crystalline compound (VIII) m.p. 194°-195° C; [α]D - 100° (c = 0.1 in CHCl3); m/e 367 (M+); PMR (CDCl3 --DMSO-d6 2:1) : 1.46 δ (d, J = 6.0 Hz, CH3 --C-5), 3.38δ (s, CH3 O) and 4.83δ (dd, J=2.5 Hz, C--1H).
2.3 g of compound (VIII) were dissolved in 80 ml of methanol and hydrogenated under pressure (15 atm) at room temperature for 62 hours in the presence of 4 g of barium carbonate and 4 g of 10% palladium on charcoal. The catalyst was filtered off and the organic solution (methanol) was evaporated to a residue. The resulting residue (1 g) was suspended in 100 ml of chloroform and the insoluble material was filtered off. The solution was then evaporated, and the resulting residue was dissolved in 20 ml of water to which was added 5 ml of glacial acetic acid. The solution was heated for 3 hours at 90° C to evaporate off the solvents and yield crystalline compound (IX) in quantitative yield m.p. 159°-160° C; at equilibrium [α]D 20 = -80° (c = 0.1 in CHCl3); m/e 210 (M--OH); PMR (DMSO-d6) : 1.03δ (d, J = 6.0 Hz, CH3 -C-5 α-anomer), 1.09δ (d, J = 6.0 Hz, CH3 -C-5 β-anomer), 1.2-1.9δ (m, C-2H2 e C--4H2), 4.60δ (dd, J = 2.0 Hz, J' = 9 Hz, C-1 Hax), 5.17δ (broad s, wH 6Hz, C-1 Heq.).
To a solution of 1 g of compound (IX) in 10 ml of anhydrous pyridine, 2 g of p-nitrobenzoyl chloride were added. After 12 hours at room temperature, the reaction mixture was poured onto ice and the resulting precipitate was washed with water until the water was neutral. The resulting crude 1-p-nitrobenzoate (mixture of α and β anomer) was dried over phosphorus pentoxide for several hours under vacuum, and then dissolved in dry methylene dichloride and saturated at 0° with anhydrous hydrogen chloride. The precipitated p-nitrobenzoic acid was filtered off under anhydrous conditions, and the 1-chloro derivative (II) was obtained in quantitative yield by evaporation of the solvent. Compound (II) can be used for the ensuing condensation reaction without further purification.
EXAMPLE 2 4'-deoxy-daunomycin
A solution of 1.5 g of daunomycinone in 150 ml of anhydrous methylene dichloride containing 0.75 g of 2,3,4,6-tetradeoxy-3-trifluoroacetamido-L-threo-hexopyranosyl chloride (II), was vigorously stirred in the presence of 10 g of molecular sieve (4 A Merck) and 0.77 g of AgSO3 CF3 in 20 ml of anhydrous diethyl ether. After two hours at room temperature, the reaction mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and the organic phase, after being separated, was evaporated under vacuum to obtain a residue. The thus obtained residue was dissolved in 50 ml of 0.1 N aqueous sodium hydroxide, and after 30 minutes at 0° C the solution was adjusted to pH 3.5 and repeatedly extracted with chloroform to eliminate the unreacted aglycone. Then the solution was ajusted to pH 8.3 and extracted with chloroform until the chloroform extracts were no longer colored. The chloroform extracts were combined, dried over anhydrous sodium sulphate and concentrated to a small volume and thereafter acidified to pH 4.5 with 0.1 N methanolic hydrogen chloride. The addition of excess diethyl ether yielded 4'-deoxydaunomycin as the hydrochloride; m.p. 160°-164° C (dec). A sample of the product was subjected to thin layer chromatography (TLC) on Merck Kieselgel F254 plates using a chloroform-methanol-water (150 : 42 : 6 v/v) solvent system. The Rf of the compound was 0.47; [α]D 20 = +296° (c = 0.05 CH3 OH).
EXAMPLE 3 4'-deoxyadriamycin
A solution of 4'-deoxy-daunomycin prepared as described in Example 2 in a mixture of methanol and dioxane was treated with bromine to form the α 14-bromo-derivative. Treatment of the 14-bromo derivative with an aqueous solution of sodium formate at room temperature for 100 hours gave 4'-deoxy-adriamycin which was isolated as the hydrochloride; m.p. 163° (dec); [α]D 20 = +320° (c = 0.05 CH3 OH) TLC on Merck Kieselgel HF buffered at pH 7 with phosphate M/15 using methylene chloride-methanol-water (10:2:02 v/v) solvent system Rf 0.13.
EXAMPLE 4
The condensation of compound II with the following anthracyclinones: 1,4-dimethyl-4-demethoxydaunomycinone, 1,4-dichloro-4-demethoxy-daunomycinone, 1,4-dibromo-4-demethoxydaunomycinone, 2,3-dimethyl-4-demethoxydaunomycinone, 2,3-dichloro-4-demethoxydaunomycinone, 2,3-dibromo-4-demethoxydaunomycinone, 1-methoxydaunomycinone in accordance with the procedure of Example 2 gives the corresponding 4'-deoxy-glycosides (daunomycin derivatives).
EXAMPLE 5
The daunomycin derivatives prepared in accordance with Example 4 can then be treated as in Example 3 to obtain the corresponding adriamycin derivatives.
Biological activity
The antitumor activity of a representative number of the novel antibiotic compounds of the invention (i.e., 4'-deoxydaunomycin and 4'-deoxy-adriamycin) was evaluated on several transplanted tumors in mice in comparison with the known antitumor agents daunomycin and adriamycin.
The results are given in the following tables.
L1210 Leukemia
Inbred BDF1 mice were intraperitoneally inoculated with 105 leukemia cells/mouse and then treated intraperitoneally one day after the tumor inoculation with varying doses of the compounds under examination. The average survival time percentage and the number of long term survivors are given in Table 1.
              TABLE 1                                                     
______________________________________                                    
           Action on L.sub.1210 Leukemia                                  
             Dose   Average  Long Term                                    
             mg/    Survival Survivors Toxic                              
Compound     kg     Time (%) (after 60 days)                              
                                       Deaths                             
______________________________________                                    
Daunomycin   2      162      --        --                                 
             4      162      --        --                                 
             6      156      --        4/10                               
4'-Deoxy-daunomycin                                                       
             4      162      --        --                                 
             8      187      --        1/10                               
             16     162      --        8/10                               
Adriamycin   2.5    145      --        --                                 
             5      155      2/20      --                                 
             10     163      2/20      3/18                               
4'-Deoxy-Adriamycin                                                       
             1      155      --        --                                 
             2      162      --        --                                 
             4      177      2/10      --                                 
             5      133      1/10      6/10                               
             10      66      --        10/10                              
______________________________________
Transplanted Gross Leukemia
Inbred C3 H female mice were intravenously inoculated with a suspension of Leukemia lymphonodes and spleen cells (2 × 106 Leukemia cells/mouse) and treated intravenously on days 1,2 and 3 after inoculation with the compounds under examination. The average survival time percentage is given in Table 2.
              TABLE 2                                                     
______________________________________                                    
           Action on Transplanted Gross Leukemia                          
             Dose   Average  Long Term                                    
             mg/    Survival Survivors Toxic                              
Compound     kg     Time (%) (after 45 days)                              
                                       Deaths                             
______________________________________                                    
Daunomycin   3.5    128      --        --                                 
             4.5    143      --        --                                 
             5.5    171      --        --                                 
4'-Deoxy-Daunomycin                                                       
             2      128      --        --                                 
             4      157      --        2/10                               
             8      100      --        9/10                               
Adriamycin   3.5    183      --        --                                 
             4.5    200      --        --                                 
             5.5    216      3/10      --                                 
4'-Deoxy-Adriamycin                                                       
             1.75   200      --        --                                 
             2.25   233      1/10      --                                 
             2.75   233      --        1/9                                
______________________________________
Ascites lymphocytic P388 Leukemia
Male CDF1 mice were intraperitoneally inoculated with 106 leukemia cells/mouse and treated intraperitoneally on the first day after inoculation with different doses of the compounds under examination. The average survival time percentage is given in Table 3.
              TABLE 3                                                     
______________________________________                                    
           Action on P.sub.388 Leukemia                                   
Compound     Dose mg/kg Average Survival Time (%)                         
______________________________________                                    
Adriamycin   2.5        218                                               
             5          209                                               
             10         264                                               
4'-Deoxy-Adriamycin                                                       
             2          204                                               
             4          218                                               
             6          236                                               
             8          245                                               
______________________________________
Solid Sarcoma 180
Swiss CD1 mice were subcutaneously grafted with fragments of neoplastic (Solid Sarcoma 180) tissue and treated intravenously on days 1, 2, 3, 4 and 5 after inoculation with different doses of the compounds under examination. The growth of the tumors was evaluated by caliper measurement on the 11th day after the tumor implants. The results are given in Table 4.
              TABLE 4                                                     
______________________________________                                    
           Activity on Solid Sarcoma 180                                  
Compound     Dose mg/kg Weight Tumor gr.                                  
                                     T/C%                                 
______________________________________                                    
Adriamycin   1.6        0.890        52                                   
             2.0        0.875        51                                   
4'-Deoxy-Adriamycin                                                       
             0.8        0.810        47                                   
             1.0        0.790        46                                   
______________________________________
Variations and modifications can, of course, be made without departing from the spirit and scope of the invention.

Claims (22)

Having thus described our invention what we desire to secure by Letters Patent and hereby claim is:
1. A compound of the formula ##STR6##wherein when a. R1 and R2 are hydrogen, R3 is a lower alkoxy group having from 1 to 4 carbon atoms; when
b. R2 is hydrogen; R1 and R3 are both hydrogen, methyl, methoxy, chlorine or bromine; and when
c. R1 and R3 are hydrogen, R2 is methyl, methoxy, chlorine or bromine.
2. A compound according to claim 1, which is 4'-deoxydaunomycin.
3. A compound according to claim 1, which is 1,4,-dimethyl-4-demethoxy-4'-deoxy-daunomycin.
4. A compound according to claim 1, which is 1,4-dichloro-4-demethoxy-4'-deoxy-daunomycin.
5. A compound according to claim 1, which is 1,4-dibromo-4-demethoxy-4'-deoxy-daunomycin.
6. A compound according to claim 1, which is 2,3-dimethyl-4-demethoxy-4'-deoxy-daunomycin.
7. A compound according to claim 1, which is 2,3-dichloro-4-demethoxy-4'-deoxy-daunomycin.
8. A compound according to claim 1, which is 2,3-dibromo-4-demethoxy-4'-deoxy-daunomycin.
9. A compound of the formula ##STR7##wherein when a. R1 and R2 are hydrogen, R3 is a lower alkoxy group having from 1 to 4 carbon atoms; when
b. R2 is hydrogen; R1 and R3 are both hydrogen, methyl, methoxy, chlorine or bromine; and when
c. R1 and R3 are hydrogen, R2 is methyl, methoxy, chlorine or bromine.
10. A compound according to claim 9, which is 4'-deoxy-adriamycin.
11. A compound according to claim 9, which is 1,4-dimethyl-4-demethoxy-4'-deoxy-adriamycin.
12. A compound according to claim 9, which is 1,4-dichloro-4-demethoxy-4'-deoxy-adriamycin.
13. A compound according to claim 9, which is 1,4-dibromo-4-demethoxy-4'-deoxy-adriamycin.
14. A compound according to claim 9, which is 2,3-dimethyl-4-demethoxy-4'-deoxy-adriamycin.
15. A compound according to claim 9, which is 2,3-dichloro-4-demethoxy-4'-deoxy-adriamycin.
16. A compound according to claim 9, which is 2,3-dibromo-4-demethoxy-4'-deoxy-adriamycin.
17. A method of inhibiting the growth of a tumor selected from the group consisting of L1210 leukemia, transplated gross leukemia, lymphocytic P388 leukemia and solid sarcoma 180 which comprises administering to a host afflicted with said tumor an amount of a compound according to claim 1 sufficient to inhibit the growth of said tumor.
18. A method according to claim 17, wherein said compound is administered intraperitoneally or intravenously.
19. A method of inhibiting the growth of a tumor selected from the group consisting of L1210 leukemia, transplanted gross leukemia, lymphocytic P388 leukemia and solid sarcoma 180 which comprises administering to a host afflicted with said tumor an amount of a compound according to claim 9 sufficient to inhibit the growth of said tumor.
20. A method according to claim 19, wherein said compound is administered intraperitoneally or intravenously.
21. A pharmaceutical composition comprising a therapeutically effective amount of a compound as claimed in claim 1 and an inert carrier therefor.
22. A pharmaceutical composition comprising a therapeutically effective amount of a compound as claimed in claim 9 and an inert carrier therefor.
US05/722,689 1975-09-26 1976-09-13 Anthracycline glycosides, their preparation and use Expired - Lifetime US4067969A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB39471/75A GB1511559A (en) 1975-09-26 1975-09-26 Anthracycline glycosides
UK39471/75 1975-09-26

Publications (1)

Publication Number Publication Date
US4067969A true US4067969A (en) 1978-01-10

Family

ID=10409731

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/722,689 Expired - Lifetime US4067969A (en) 1975-09-26 1976-09-13 Anthracycline glycosides, their preparation and use

Country Status (16)

Country Link
US (1) US4067969A (en)
JP (1) JPS5242869A (en)
AT (1) AT347582B (en)
AU (1) AU504480B2 (en)
BE (1) BE846548A (en)
CA (1) CA1060002A (en)
CH (1) CH606082A5 (en)
DE (1) DE2642837C3 (en)
DK (1) DK146626C (en)
FR (1) FR2325659A1 (en)
GB (1) GB1511559A (en)
HK (1) HK1182A (en)
NL (1) NL174015C (en)
SE (2) SE429655B (en)
SU (2) SU670226A3 (en)
ZA (1) ZA765736B (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166848A (en) * 1976-11-16 1979-09-04 Societa Farmaceutici Italia S.P.A. Anthracycline derivatives, their preparation and use
US4183919A (en) * 1976-12-22 1980-01-15 Farmitalia Carlo Erba S.P.A. Antitumor glycosides, process for their preparation including intermediates therefor and their use
US4191755A (en) * 1977-05-05 1980-03-04 Farmitalia Carlo Erba S.P.A. Novel daunomycin derivatives, their aglycones and the use thereof
US4191756A (en) * 1977-05-05 1980-03-04 Farmitalia Carlo Erba S.P.A. Daunomycin derivatives, their aglycones and the use thereof
WO1980000305A1 (en) * 1978-07-26 1980-03-06 Us Commerce 7-0-(2,6-dideoxy-a-l-lyxo-hexopyranosyl)-desmethoxydaunomycinone,adriamycinone,and carminomycinone
WO1980002112A1 (en) * 1979-04-02 1980-10-16 H Newman Novel heterocyclic anthracycline compounds
US4325947A (en) * 1981-05-12 1982-04-20 Farmitalia Carlo Erba S.P.A. 4-Demethoxy-4'-deoxydoxorubicin
US4325946A (en) * 1979-09-01 1982-04-20 Farmitalia Carlo Erba S.P.A. Anthracycline glycosides, their preparation, use and compositions thereof
US4345070A (en) * 1980-09-29 1982-08-17 Farmitalia Carlo Erba S.P.A. Process for the preparation of 4'-deoxy-daunorubicin and 4'-deoxy-doxorubicin
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US4366149A (en) * 1980-11-01 1982-12-28 Erba Farmitalia Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
US4393052A (en) * 1980-11-01 1983-07-12 Farmitalia Carlo Erba S.P.A. Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
US4477444A (en) * 1981-01-21 1984-10-16 Farmitalia Carlo Erba S.P.A. Antracycline glycosides, pharmaceutical compositions and method of use
US4514561A (en) * 1983-04-15 1985-04-30 Research Corporation Process for preparing α-L N-acetyl daunosaminide
US4522815A (en) * 1982-05-24 1985-06-11 Farmitalia Carlo Erba S.P.A. Anthracycline glycosides
US4562177A (en) * 1982-08-17 1985-12-31 The Ohio State University Research Foundation 3'-Amino-2' halo-anthracycline antibiotics
US4591636A (en) * 1980-07-18 1986-05-27 Hoffmann-La Roche Inc. Anthracycline glycosides
GB2169285A (en) * 1985-01-05 1986-07-09 Erba Farmitalia 4'-Deoxydoxorubicin-14-esters
DE3500023A1 (en) * 1985-01-02 1986-07-10 Farmitalia Carlo Erba S.p.A., Mailand/Milano 4'-Deoxyanthracycline esters
WO1990007519A1 (en) * 1988-12-28 1990-07-12 Board Of Regents, The University Of Texas System 3'-deamino analogs of esorubicin and methods for their use
US4946831A (en) * 1985-08-02 1990-08-07 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4973674A (en) * 1987-04-14 1990-11-27 Farmitalia Carlo Erba S.R.L. Chiral synthesis of anthracyclines from substituted anthraquinones
US4987126A (en) * 1988-02-10 1991-01-22 Farmitalia Carlo Erba S.R.L. 3'-deamino-4'-deoxy-4'-amino anthracyclines
EP0426653A1 (en) 1987-04-21 1991-05-08 PHARMACIA S.p.A. 4-demethoxy-4-amino-anthracyclines
US5045534A (en) * 1987-11-10 1991-09-03 Farmitalia Carlo Erba S.R.L. 4-demethoxy-4'-amino-4'-deoxy-anthracycline derivatives
US5132290A (en) * 1988-01-19 1992-07-21 The Board Of Regents, The University Of Texas System Esters of 3'-deaminodoxorubicin and liposomal compositions thereof
US5942605A (en) * 1998-03-03 1999-08-24 Gem Pharmaceuticals, Inc. 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US6107285A (en) * 1985-08-02 2000-08-22 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA814722B (en) * 1980-07-18 1982-07-28 Hoffmann La Roche Novel anthracycline glycosides
JPS57142981A (en) * 1981-01-21 1982-09-03 Erba Carlo Spa Anthracycline glycoside, manufacture and tumor generation inhibiting drug containing same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697652A (en) * 1968-08-22 1972-10-10 Rotta Research Lab N-acetylglucosamine for treating degenerative afflictions of the joints
US3803124A (en) * 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
US4020270A (en) * 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2183710A1 (en) * 1972-05-06 1973-12-21 Farmaceutici Italia Daunomycin (hydrochloride) prepn - by reaction of daunomycinone with daunosamines, useful as antitumour agent and anti-leucemic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803124A (en) * 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
US3697652A (en) * 1968-08-22 1972-10-10 Rotta Research Lab N-acetylglucosamine for treating degenerative afflictions of the joints
US4020270A (en) * 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166848A (en) * 1976-11-16 1979-09-04 Societa Farmaceutici Italia S.P.A. Anthracycline derivatives, their preparation and use
US4183919A (en) * 1976-12-22 1980-01-15 Farmitalia Carlo Erba S.P.A. Antitumor glycosides, process for their preparation including intermediates therefor and their use
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US4191755A (en) * 1977-05-05 1980-03-04 Farmitalia Carlo Erba S.P.A. Novel daunomycin derivatives, their aglycones and the use thereof
US4191756A (en) * 1977-05-05 1980-03-04 Farmitalia Carlo Erba S.P.A. Daunomycin derivatives, their aglycones and the use thereof
WO1980000305A1 (en) * 1978-07-26 1980-03-06 Us Commerce 7-0-(2,6-dideoxy-a-l-lyxo-hexopyranosyl)-desmethoxydaunomycinone,adriamycinone,and carminomycinone
US4201773A (en) * 1978-07-26 1980-05-06 The United States Of America As Represented By The Department Of Health, Education And Welfare 7-O-(2,6-Dideoxy-α-L-lyxo-hexopyranosyl)-daunomycinone, desmethoxy daunomycinone, adriamycinone, and carminomycinone
WO1980002112A1 (en) * 1979-04-02 1980-10-16 H Newman Novel heterocyclic anthracycline compounds
US4259476A (en) * 1979-04-02 1981-03-31 Kende Andrew S Novel heterocyclic anthracycline compounds
US4325946A (en) * 1979-09-01 1982-04-20 Farmitalia Carlo Erba S.P.A. Anthracycline glycosides, their preparation, use and compositions thereof
US4591636A (en) * 1980-07-18 1986-05-27 Hoffmann-La Roche Inc. Anthracycline glycosides
US4345070A (en) * 1980-09-29 1982-08-17 Farmitalia Carlo Erba S.P.A. Process for the preparation of 4'-deoxy-daunorubicin and 4'-deoxy-doxorubicin
US4366149A (en) * 1980-11-01 1982-12-28 Erba Farmitalia Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
US4393052A (en) * 1980-11-01 1983-07-12 Farmitalia Carlo Erba S.P.A. Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
US4477444A (en) * 1981-01-21 1984-10-16 Farmitalia Carlo Erba S.P.A. Antracycline glycosides, pharmaceutical compositions and method of use
US4325947A (en) * 1981-05-12 1982-04-20 Farmitalia Carlo Erba S.P.A. 4-Demethoxy-4'-deoxydoxorubicin
US4522815A (en) * 1982-05-24 1985-06-11 Farmitalia Carlo Erba S.P.A. Anthracycline glycosides
US4562177A (en) * 1982-08-17 1985-12-31 The Ohio State University Research Foundation 3'-Amino-2' halo-anthracycline antibiotics
US4514561A (en) * 1983-04-15 1985-04-30 Research Corporation Process for preparing α-L N-acetyl daunosaminide
DE3500023A1 (en) * 1985-01-02 1986-07-10 Farmitalia Carlo Erba S.p.A., Mailand/Milano 4'-Deoxyanthracycline esters
GB2169285A (en) * 1985-01-05 1986-07-09 Erba Farmitalia 4'-Deoxydoxorubicin-14-esters
US6107285A (en) * 1985-08-02 2000-08-22 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4946831A (en) * 1985-08-02 1990-08-07 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4973674A (en) * 1987-04-14 1990-11-27 Farmitalia Carlo Erba S.R.L. Chiral synthesis of anthracyclines from substituted anthraquinones
EP0426653A1 (en) 1987-04-21 1991-05-08 PHARMACIA S.p.A. 4-demethoxy-4-amino-anthracyclines
US5045534A (en) * 1987-11-10 1991-09-03 Farmitalia Carlo Erba S.R.L. 4-demethoxy-4'-amino-4'-deoxy-anthracycline derivatives
US5132290A (en) * 1988-01-19 1992-07-21 The Board Of Regents, The University Of Texas System Esters of 3'-deaminodoxorubicin and liposomal compositions thereof
US4987126A (en) * 1988-02-10 1991-01-22 Farmitalia Carlo Erba S.R.L. 3'-deamino-4'-deoxy-4'-amino anthracyclines
WO1990007519A1 (en) * 1988-12-28 1990-07-12 Board Of Regents, The University Of Texas System 3'-deamino analogs of esorubicin and methods for their use
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US5942605A (en) * 1998-03-03 1999-08-24 Gem Pharmaceuticals, Inc. 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them

Also Published As

Publication number Publication date
FR2325659B1 (en) 1982-08-20
DE2642837A1 (en) 1977-04-07
AU504480B2 (en) 1979-10-18
DE2642837B2 (en) 1982-01-07
SE8001616L (en) 1980-02-29
DE2642837C3 (en) 1982-08-12
NL7610139A (en) 1977-03-29
FR2325659A1 (en) 1977-04-22
ZA765736B (en) 1977-11-30
BE846548A (en) 1977-03-24
AU1802576A (en) 1978-04-06
SE429655B (en) 1983-09-19
CA1060002A (en) 1979-08-07
DK146626C (en) 1984-04-30
JPS5242869A (en) 1977-04-04
NL174015C (en) 1984-04-16
ATA707276A (en) 1978-05-15
JPS6123189B2 (en) 1986-06-04
SU730310A3 (en) 1980-04-25
HK1182A (en) 1982-01-22
DK146626B (en) 1983-11-21
GB1511559A (en) 1978-05-24
SU670226A3 (en) 1979-06-25
SE7610564L (en) 1977-03-27
NL174015B (en) 1983-11-16
AT347582B (en) 1979-01-10
CH606082A5 (en) 1978-10-13
DK426076A (en) 1977-03-27
SE435514B (en) 1984-10-01

Similar Documents

Publication Publication Date Title
US4067969A (en) Anthracycline glycosides, their preparation and use
US4112076A (en) Epi-daunomycin and epi-adriamycin compounds and method of use
US4058519A (en) Adriamycins and uses thereof
US4046878A (en) Daunomycin analogues, their preparation and use
US4039663A (en) Daunomycins, process for their uses and intermediates
US4025623A (en) 4'-Epi-6'-hydroxyadriamycin and method of use
US5304687A (en) Morpholinyl derivatives of doxorubicin and process for their preparation
US4366149A (en) Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
US4325946A (en) Anthracycline glycosides, their preparation, use and compositions thereof
US4188377A (en) Carminomycin derivatives, their preparation and use
EP0014853A1 (en) Anthracycline derivatives, a process for their preparation and pharmaceutical compositions containing them
US4183919A (en) Antitumor glycosides, process for their preparation including intermediates therefor and their use
US4684629A (en) 3'-deamino-3'-hydroxy-4'-deoxy-4'-amino doxorubicin and related daunorubicin
US4393052A (en) Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
US4303785A (en) Antitumor anthracycline antibiotics
US4839346A (en) Antitumor anthracycline glycosides, intermediates thereof, and composition and use thereof
US4199571A (en) Substituted anthracyclines, their preparation and use
US4322412A (en) Anthracycline glycosides, their preparation, use and compositions thereof
US4169142A (en) Disaccharide analogs of antitumor anthracyclines, process for their preparation and use thereof
US4131649A (en) Daunorubicin derivatives, their preparation and their use
KR950004897B1 (en) Process for preparing anthracycline derivatives
US4146616A (en) Antitumor compounds, their preparation and use
US4265885A (en) Anthracyclines containing branched-chain amino-deoxy sugars
US4749693A (en) Nitro anthracyclines, process for their preparation and use thereof
US4276289A (en) Antitumor glycosides, their preparation and use

Legal Events

Date Code Title Description
AS Assignment

Owner name: FARMITALIA CARLO ERBA S.P.A.,

Free format text: MERGER;ASSIGNORS:CARLO ERBA S.P.A.;SOCIETA FARMACEUTICI ITALIA S.P.A., KNOWN AS FARMITALIA S.P.A.;REEL/FRAME:003981/0134

Effective date: 19801007

AS Assignment

Owner name: FARMITALIA CARLO ERBA S.R.L., STATELESS

Free format text: CHANGE OF NAME;ASSIGNOR:FARMITALIA CARLO ERBA S.P.A.;REEL/FRAME:005060/0892

Effective date: 19880310